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Take home message: Persistent hyperglycemia is associated with significant neuronal and glial 
changes during critical illness. Preventing hyperglycemia with insulin infusion during critical illness 
holds promise as a neuroprotective strategy to prevent acute brain dysfunction as well as long-term 
cognitive impairment in survivors of critical illness. When occurring, hypoglycemia should be 
corrected promptly, avoiding overcorrection with excessive glucose reperfusion. 
A 140-character tweet: Preventing hyperglycemia in ICU holds promise to protect against acute 
brain dysfunction and long-term cognitive impairment. 
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ABSTRACT 
Purpose: Dysglycemia is a characteristic feature of critical illness associated with adverse outcome. 
Whether dysglycemia contributes to brain dysfunction during critical illness and long-term 
neurological complications is unclear. We give an overview of glucose metabolism in brain and 
review the literature on critical illness-induced dysglycemia and brain. 
Methods: Medline database search using relevant search terms on dysglycemia, critical illness, acute 
brain injury/dysfunction, and randomized controlled trial. 
Results: Hyperglycemia has been associated with deleterious effects on the nervous system. 
Underlying mechanisms in critical illness remain largely speculative and are often extrapolated from 
knowledge in diabetes-mellitus. Increased hyperglycemia-induced blood-brain-barrier permeability, 
oxidative stress and microglia activation may play a role and compromise neuronal and glial cell 
integrity. Hypoglycemia is feared as critically ill patients cannot recognize or communicate 
hypoglycemic symptoms, which furthermore are masked by sedation and analgesia. However, 
observational data on impact of brief hypoglycemia on the brain in critical illness are controversial. 
Secondary analysis of two large randomized studies suggested neuroprotection by strict glycemic 
control with insulin during intensive care, with lowered intracranial pressure, reduction of seizures, 
and better long-term rehabilitation in patients with isolated brain injury, and reduced incidence of 
critical illness-polyneuromyopathy in the general critically ill patient population. Several subsequent 
studies failed to reproduce neurological benefit, likely explained by methodological issues, among 
which divergent achieved glucose levels and inaccurate glucose monitoring tools. 
Conclusions: Preventing hyperglycemia during critical illness holds promise as neuroprotective 
strategy to preserve brain cell viability and prevent acute brain dysfunction and long-term cognitive 
impairment in survivors. 
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INTRODUCTION 
Dysglycemia, in the form of hyperglycemia, hypoglycemia and/or marked glucose variability, is a 
characteristic feature of critical illness, whether patients have previously diagnosed diabetes or not [1]. 
Various mechanisms contribute, including pre-existing abnormal glucose metabolism, systemic and 
immune responses, and use of medications such as steroids and parenteral nutrition [1]. Both 
hyperglycemia and hypoglycemia have been associated with significant morbidity and mortality of 
these patients [2]. By inducing injury to vulnerable areas of the nervous system, critical illness-
induced dysglycemia may contribute to the development of neurologic complications of critical 
illness, including delirium and polyneuropathy in ICU and long-term cognitive impairment in ICU 
survivors [3, 4]. Interestingly, onset of delirium is characterized by an acute brain dysfunction 
involving the hippocampus and frontal cortex, two areas that are extremely vulnerable to metabolic 
insults, such as hypoxia, ischemia, hypoglycemia and possibly hyperglycemia [5, 6]. However, 
whether a causal relation exists between dysglycemia and brain dysfunction or injury in critically ill 
patients remains unclear. This review provides an overview of brain glucose metabolism and of the 
data on the effects of dysglycemia and blood glucose control with insulin on the brain during critical 
illness. 
A medline database search was conducted using relevant search terms on dysglycemia 
(hyperglycemia, hypoglycemia, glucose variability, insulin) and brain dysfunction or injury (delirium, 
cognitive dysfunction, acute brain injury). For the effects of blood glucose control with insulin on the 
nervous system we focused on evidence from randomized controlled studies conducted in critically ill 
patients with or without acute brain injury. 
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BRAIN GLUCOSE METABOLISM 
 
Glucose is the most important substrate for brain. Under normal conditions, brain glucose 
concentration approximates 25-30% of the circulating levels and thus is highly dependent on plasma 
concentrations [7]. The normal cerebral glucose demand is approximately 5 mg/100 g of brain 
tissue/min, but with a higher demand of 5-15 mg/100 g of brain tissue/min in areas with greater 
metabolic activities, i.e. cortex basal ganglia and hippocampus. 
 
Glucose transport  
Before brain cells can take up glucose to support their metabolism, glucose must cross the blood-brain 
barrier (BBB). The concentration gradients for glucose and other nutrients are from blood to brain and 
thus regulated by brain metabolic utilization and plasma concentration [7]. Glucose is transported 
across the BBB via the 55kDa-isoform of glucose transporter (GLUT) 1, which is exclusively 
expressed in endothelial cells from the BBB (Table 1) [8]. The density of GLUT1 at the abluminal 
membrane is higher than at the luminal membrane [8]. This asymmetrical distribution provides a 
homeostatic control of glucose entry into the brain, by preventing accumulation in brain interstitial 
fluid at levels higher than in blood. The adult brain adapts to hypoxia by increasing GLUT1 at the 
BBB, mediated by hypoxia-inducible-factor-1. Another isoform of GLUT-1, that of 45kDa, is mainly 
localized in astrocytes and epithelial cells. GLUT1 mRNA is acutely induced in hypothalamus and 
cortex during insulin-induced hypoglycemia [9]. This is likely explained by hypoglycemia, and not by 
hyperinsulinemia, since fasting is characterized by low insulin and low glucose levels and also induces 
GLUT1 mRNA. Whether reverse transport adaptation takes place during hyperglycemia is less clear. 
A study in healthy humans suggested no major modification in maximal transport velocity or affinity 
to the BBB glucose transporter during acute hyperglycemia [10]. Down-regulation of GLUT1 has 
been reported in cells cultured under hyperglycemia [11]. In contrast, Pelligrino et al. found an 
increased BBB glucose transport in chronic hyperglycemia [12]. Further studies are needed to clarify 
whether the human brain possesses additional adaptive mechanisms that modulate BBB glucose 
transport in case of hyperglycemia or hypoglycemia. 
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The human brain also expresses several other GLUTs (Table 1), including GLUT3 for neuronal 
glucose uptake [8]. Recent studies suggest a role for GLUT2 in monitoring changes in brain glucose 
levels, based on its expression in specialized glucose-sensing cells in the paraventricular nucleus of the 
hypothalamus, arcuate nucleus and lateral hypothalamic region. GLUT5 is involved in transport of 
glucose and mainly fructose, in brain exclusively in microglia [13]. The insulin-sensitive GLUT4 and 
GLUT8 might contribute to CNS effects of insulin. GLUT4 expression is limited to neuronal bodies 
and dendrites and often colocalises with insulin receptors. Cellular GLUT4 localization in brain may 
be sensitive to changes in insulin levels as described for muscle and adipose tissue. GLUT8 is present 
in neurons and GLUT8 knockout (Slc2a8-/-) mice showed behavioural alterations, presumably due to 
deficient glucose metabolism [14]. 
Apart from glucose transporters, several monocarboxylate transporters are found in the brain (Table 
1). Astrocytes mainly express the lactate transporters MCT1 and MCT4, while neurons mainly express 
MCT1 and MCT2 [8].  
Widely varying substrate affinities (with the lower the Km the higher the affinity) have been reported 
for the GLUTs and MCTs (Table 1), with a higher apparent substrate affinity for the neuronal 
transporters (GLUT3, MCT2) than for those in astrocytes (GLUT1, MCT1, MCT4) [8, 15]. It thus 
seems likely that any potential neurotoxicity of persistent hyperglycemia is driven indirectly rather 
than directly as, according to Km values, neuronal transporters appear to be saturated under 
physiologic conditions with normal fasting blood glucose levels of 4.4-6.1 mmol/l. In contrast, glucose 
transport to astrocyes and/or microglial cells may increase significantly under high glucose levels, 
inducing deleterious changes, including excessive glycolyis and accumulation of lactic acid in brain 
tissue, release of proinflammatory cytokines by glial cells, and subsequent neuronal damage. Caution 
is warranted, however, as the reported affinities depend on in vitro cell culture conditions, including 
pH, substrate analogue used, cell type and purity in which the transporters are expressed, and 
coexpression of other transporters and enzymes that phosphorylate glucose [8, 15].  
Interestingly, insulin is not required for glucose entry into the brain or metabolism by neurons or glial 
cells [16]. Nevertheless, the brain is rich in insulin receptors with substantial regional variation, and 
especially abundant in the olfactory bulb, hippocampus, hypothalamus and amygdala.  
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 Brain energetics and glucose metabolism 
Glucose represents the brain’s only substrate under normal physiologic conditions. Under basal 
conditions, 90% of glucose uptake in neurons is aerobically used for production of energy to maintain 
ionic homeostasis. The brain contains less than 1 mmol/kg of free glucose reserve. Astrocytes, but not 
neurons, are able to store glycogen. This capacity gives astrocytes a key role in the regulation of brain 
metabolic responses to activity, as they can rapidly convert glycogen to pyruvate/lactate to be further 
metabolized in the tricarboxylic acid cycle or used for glutamate biosynthesis [17]. The release of 
lactate can support neuronal function for a limited period [17]. During sustained neuronal activation, 
reflected by glutamatergic activity, glutamate-induced glycolysis in astrocytes provides lactate as 
preferential oxidative substrate to neurons, a concept known as “astrocyte-neuron lactate shuttle” 
(Figure 1). In addition to glucose, lactate is then taken up by activated neurons via specific MCTs and 
oxidized to contribute to their energy needs. Actually, recent in vivo rat studies added evidence that 
lactate represents a relevant neuronal energy source [18]. First, lactate largely maintained neuronal 
activity and integrity in the absence of glucose, as loss of a voltage-sensitive dye signal found during 
severe insulin-induced hypoglycemia was completely prevented by lactate infusion, suggesting direct 
neuroprotection. Second, the brain preferred lactate as energy substrate over glucose when both 
substrates were available. Third, lactate appeared readily metabolized by non-injured brain in an 
activity-dependent manner. Other studies suggested that neuronal lactate import is essential for long-
term memory formation and maintenance of long-term potentiation of synaptic strength [19]. 
Neuroprotection by exogenous lactate has been documented in various conditions (prolonged 
starvation, diabetes, ischemia), but beneficial effects of lactate on the acutely injured human brain are 
scarce. Preliminary clinical data suggest that hypertonic lactate solutions may improve cerebral energy 
metabolism and may be effective to treat elevated intracranial pressure after traumatic brain injury 
[20], though larger studies are needed. 
Ketone bodies, such as β-hydroxybutyrate and acetoacetate, are other energy sources for brain 
metabolism during states as fasting or ketoacidosis. Under starvation conditions, ketone utilization can 
contribute up to 30% of the brain’s fuel for oxidative metabolism.   
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DYSGLYCEMIA AND THE BRAIN IN CRITICAL ILLNESS 
 
Clinical complications of dysglycemia develop much faster as in patients with diabetes. We 
summarize the responses triggered in brain by impaired glucose homeostasis and their impact on the 
brain in diabetes and critical illness. 
 
Hyperglycemia 
Patients with type 1 diabetes who have been exposed to chronic hyperglycemia show marked 
structural brain abnormalities, including hippocampal injury, changes in white matter microstructure 
and cerebral atrophy, contributing to neurocognitive impairment [21]. Elderly patients with diabetes 
have accelerated progression of brain atrophy with significant consequences on cognition [22]. 
Experimental data in streptozotocin-induced diabetes suggest that diabetes impairs astrocyte viability 
and function. This is illustrated by decreased glial acidic fibrillary protein (GFAP) levels in cerebral 
cortex, hippocampus and cerebellum at 8 weeks, together with attenuated GFAP immunoreactivity at 
4 weeks in hippocampus and white matter [23]. Furthermore, hyperglycemia and diabetes impair gap-
junctional communication in various cell types and notably astrocytes. Insulin treatment prevented 
these diabetes-induced astrocyte alterations. 
Association studies on stress hyperglycemia and brain damage are mostly performed in the setting of 
traumatic brain injury or cerebral ischemia. Hyperglycemia is frequently observed in patients with 
acute brain injury and is associated with an increased risk of death and of poor functional recovery in 
survivors [24]. In cerebral ischemia, hyperglycemia has various deleterious effects, including 
increased infarct volume, impaired recanalization and decreased reperfusion, increased damage caused 
by reperfusion injury and direct tissue injury [25]. After ischemia and reperfusion injury, experimental 
data suggest that hyperglycemia not only affects neurons, but also contributes to astrocyte death by 
increased DNA oxidation [26]. An association between hyperglycemia and microglial apoptosis was 
suggested in patients who had died from septic shock [27]. In patients surviving the acute respiratory 
distress syndrome hyperglycemia predicted adverse cognitive sequellae [28]. Hyperglycemia may 
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theoretically contribute to brain injury in critical illness by different mechanisms. An up-regulation of 
neuronal and astrocytic glucose transporters through regulators that are increased in critical illness and 
acute brain injury could lead to exaggerated passive transport of glucose into the brain. BBB 
disruption in systemic inflammation and sepsis have also been suggested [29]. The consequent 
neuronal glucose overload may induce exaggerated oxidative stress, via overactivation of NADPH 
oxidase, with generation or deficient scavenging of reactive oxygen species (ROS) [30]. In a 
neuropathological study in non-survivors of critical illness, hyperglycemia was shown to aggravate 
critical illness-induced neuropathological changes [31]. Patients with uncontrolled hyperglycemia 
(14.1±4.6 mmol/l) showed increased microglial activation, an important reduction in astrocyte density 
and activation status, more than 9-fold increased neuronal and glial apoptosis and a 1.5-2-fold increase 
in damaged neurons in hippocampus and frontal cortex. Most abnormalities were attenuated with 
moderate hyperglycemia (9.6±1.8 mmol/l) and virtually absent with normoglycemia (5.8±0.5 mmol/l). 
Similar findings were observed after 7 days in frontal cortex of hyperglycemic (17.5±1.8 mmol/l) 
versus normoglycemic (4.7±0.7 mmol/l) critically ill rabbits. After 3 days of critical illness, only 
microglial changes were observed under hyperglycemia (18.6±0.9 mmol/l). These findings suggest 
that pro-inflammatory effects of hyperglycemia could induce over-activation of microglia, leading to 
exaggerated and prolonged local production of inflammatory mediators in the brain. This would affect 
neuronal functioning and viability, leading to astroglial cell apoptosis, microglial activation and 
subsequent neuronal damage and apoptosis [31]. Interestingly, hyperglycemia has also been associated 
with apoptosis of microglial cells in non-survivors of critical illness [27]. 
Increased oxidative stress and inflammatory responses may also play a role in reperfusion injury and 
mitochondrial dysfunction and anaerobic glycolysis in direct tissue injury in the brain [25].  
 
Hypoglycemia 
Transient hypoglycemia deprives the brain of its major fuel and may result in functional brain failure 
[32]. Normally, fasting circulating glucose levels in adults range from 4.4 to 6.1 mmol/l. Initially, 
declining plasma glucose levels activate defences against hypoglycemia. First, insulin secretion 
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decreases when blood glucose levels drop below the lower limit of normal. Below 3.8 mmol/l, 
increments in pancreatic β-cells’ glucagon and adrenomedullary epinephrine secretion occur. If the 
aforementioned mechanisms fail to abort the hypoglycemic episode, lower glucose levels (below 3.5 
mmol/l) induce autonomic symptoms, including anxiety, tachycardia, sweating and mydriasis. These 
symptoms usually prompt the behavioral defence and food ingestion. If glycemia falls below 2.8-3.0 
mmol/l, neuroglycopenic symptoms, such as delirium or seizures can be seen. Stupor and coma may 
occur at glucose levels below 2.3-2.7 mmol/l [33]. As the blood glucose levels drop to the range of 1-2 
mmol/l, theta waves increase and delta waves appear on electroencephalogram. In rats, hypoglycemia 
did not induce neuronal death unless the electroencephalogram became isoelectric, whatever the blood 
glucose level [34]. Hypoglycemic brain injury differs from ischemia in its neuropathologic 
distribution. In hypoglycemia, necrosis of the hippocampal dentate gyrus can occur and a predilection 
for the superficial layers 2 and 3 of the cortex is sometimes seen [6]. Cerebellum and brainstem are 
universally spared. As described by Sakel in 1937, insulin-induced coma was performed in humans for 
a period of 30 minutes to treat schizophrenia and drug addiction [35]. A 60-minute duration led to 
tragic results, as “reversible coma” was transformed into “irreversible coma” and the patient would no 
longer wake up with glucose administration [6]. More recent experimental data suggest that 10-20 
minutes of isoelectric hypoglycemia induces significant neuronal damage in subiculum, hippocampus, 
and caudate nucleus [36]. Repeated MRI images in diabetes patients in a persistent vegetative state 
after at least 8 hours of hypoglycemia revealed specific lesions in the bilateral basal ganglia, cerebral 
cortex, substantia nigra and hippocampus, which suggests the particular vulnerability of these areas to 
hypoglycemia [37]. Interestingly, neuronal damage may be triggered during glucose reperfusion after 
hypoglycemia, rather than by the hypoglycemic episode itself [30]. 
Several mechanisms are thought to be involved in hypoglycemia-induced neuronal death. During 
hypoglycemia, glycolytic flux is decreased, thus lowering tissue levels of lactate and pyruvate. The 
resulting shortage of acetyl-CoA, with which oxaloacetate condenses, induces a transamination 
(oxaloacetate + glutamate => aspartate + α-ketoglutarate) that leads to an increase in brain tissue 
aspartate and decrease in glutamate, while both are increased in the extracellular space. The 
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extracellular aspartate released during hypoglycemia damages neurons by an excitotoxic mechanism. 
During hypoglycemia, gamma-amino-butyric acid (GABA) is released in the extracellular space [38]. 
However, its inhibitory effects are insufficient and the balance shifts toward excitation, which is why 
seizures can be seen. In addition, profound tissue alkalosis develops, due to increased ammonia 
production as the cell catabolizes proteins and deaminates amino acid and to shortage of lactate [6]. 
Other mechanisms include a series of events in which nitric oxide production triggers vesicular zinc 
release, in turn activating NADPH oxidase and ROS production, as well as poly-ADP-ribose 
polymerase (PARP-1) and mitochondrial permeability transition [36]. Suh et al. provided evidence 
that hypoglycemic superoxide production and neuronal death were increased by NADPH oxidase 
activation during glucose reperfusion rather than by hypoglycemia itself [30]. Several mechanisms 
involved in hypoglycemia-induced neuronal injury (Zn2+ release, ROS production, microglia 
activation) appeared inhibited by hypothermia and aggravated by hyperthermia during glucose 
reperfusion [39]. 
Hypoglycemia in critically ill patients is a feared complication. Patients may be unable to recognize or 
communicate hypoglycemic symptoms, because of altered mental status, intubation or the severe 
illness itself. Furthermore, clinical symptoms of the autonomic response to hypoglycemia (sweating, 
tachycardia, tremor) and central nervous symptoms (dizziness, blurred vision, confusion, altered 
mental status, and eventually seizures) may be masked by concomitant diseases or treatments 
(sedation, analgesia, mechanical ventilation). In two large clinical studies, a brief episode of severe 
hypoglycemia <2.2 mmol/l did not cause early deaths, coincided with only minor immediate and 
transient morbidity in a minority of patients, and did not lead to late neurological sequellae among 
hospital survivors [40]. Nevertheless, apart from hyperglycemia also hypoglycemia has been 
associated with an increased risk of ICU or in-hospital death in a dose-response, even when mild, with 
greater risk the lower the glucose levels fall [41-43]. Hypoglycemia has been associated with lower 
performance in one domain of a full range of cognitive functions (visuospatial skills) at least one year 
after critical illness in adult patients, but hyperglycemia and glycemic fluctuations were as well and 
hence could not be excluded as confounders [44]. No matching for baseline risk factors had been 
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performed. Interestingly, patients with a higher severity of illness have a higher risk of developing a 
hypoglycemic episode [2, 41]. Data on the potential impact of hypoglycemia on the brain in critical 
illness are scarce. Microdialysis studies in acute brain injury patients suggested that even 
normoglycemia may be detrimental by dangerously lowering brain glucose levels, contributing to 
metabolic crisis based on an increased lactate/pyruvate ratio [45], though cause and consequence could 
not be differentiated. Interestingly, a patient who experienced extreme hypoglycemia for several hours 
in ICU made an uneventful recovery, with no apparent neurological dysfunction at discharge, no 
neurological or cognitive symptoms at six months follow-up, and normal clinical examination, EEG 
and brain CT scan one year later [46]. However, irreversible brain injury and fatal outcome have been 
reported for another patient with prolonged extreme hypoglycemia [47]. 
Translating to clinical practice, it is clear that blood glucose levels should be carefully monitored to 
quickly detect and correct hypoglycemic episodes, to minimise any risk of irreversible brain injury. 
Overcorrection should be avoided as excessive glucose reperfusion may worsen neurological injury. 
 
Glucose variability 
Blood glucose variability, reflected by the standard deviation of blood glucose levels in ICU, have 
been associated with patient outcomes, including short-term mortality in general critically ill patients 
[2, 48, 49], and neurologic outcomes in patients with acute brain injury [50, 51]. Reduced mortality 
with intensive insulin therapy in the Leuven studies could not be attributed to an effect on blood 
glucose amplitude variation [2]. Nevertheless, reducing amplitude variation and entropy of the blood 
glucose signal, irrespective of blood glucose concentration, may produce clinical benefits, including 
neuroprotection, by reducing glucose reperfusion injury. So far, randomized clinical trials targeting 
blood glucose variability in patients with acute brain injury are lacking. 
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IS BLOOD GLUCOSE CONTROL WITH INSULIN DURING CRITICAL ILLNESS 
NEUROPROTECTIVE? 
Randomized controlled studies in critically ill patients showed that blood glucose control with 
intensive insulin therapy (IIT) may reduce morbidity and mortality [52-54]. These studies also 
suggested that IIT beneficially affects the central and peripheral nervous system of the patients [55, 
56]. Clinical neuroprotective effects included reduction of intracranial pressure, reduction of seizures, 
and better long-term rehabilitation in patients with isolated brain injury, together with a lower 
incidence of critical illness-induced neuromyopathy. Subsequent randomized controlled studies in 
critically ill patients with acute brain injury [57-63] or with acute ischemic stroke [64-66] showed 
mostly no benefit on neurological outcomes (Table 2). A recent systematic review on acute ischaemic 
stroke concluded that intravenous insulin administration aiming to maintain serum glucose within a 
specific range did not improve the neurological deficit [67]. Interestingly, however, two meta-analyses 
conducted in neurocritical care patients suggested better neurological outcome with insulin therapy, 
despite an increased risk of hypoglycemia, especially when glucose levels in the conventional 
glycemic control group were permitted to be relatively high and glucose limits tightened in the strict 
glycemic control group, and especially when study quality improved [68, 69]. Important 
methodological differences in glucose regulation and quality might account for the discrepancies 
between the individual studies [70]. These include different target ranges for blood glucose and 
achieved glucose levels in control and intervention groups (Table 2). Other aspects are differences in 
routes for insulin administration, types of infusion-pumps, sampling sites, and accuracies of glucose 
monitoring tools [70]. A center participating in NICE-SUGAR [71] showed inaccurate, mostly 
substantially higher glucose levels with the Lifescan point-of-care instrument than with the blood gas 
analyzer. This difference could be even higher than the difference achieved among the study arms and 
likely increased the chance for undetected hypoglycemia. Also different nutritional strategies and 
varying levels of expertise may have contributed to the different outcomes [70]. A post-hoc study of 
NICE-SUGAR like other studies showed an association of both iatrogenic and spontaneous 
hypoglycemia with an increased risk of death, though could not prove any causal relationship [72]. 
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Nevertheless, it is thought that the potential benefit of IIT may thus be negated by an increased 
incidence of severe hypoglycemia [52, 53, 71], which might be per se deleterious for the CNS, either 
directly [6], or indirectly during glucose reperfusion [30]. However, neuropathological alterations in 
post-mortem brain biopsies of hippocampus and frontal cortex appeared comparable for patients who 
experienced a brief episode of severe hypoglycemia and those who did not, findings that were 
confirmed in vivo in critically ill animals [31]. A recent randomized controlled study in critically ill 
children also found a reduced morbidity and mortality with IIT [54]. In this study, IIT did not evoke 
neurological damage detectable by circulating levels of S100B (marker of astrocyte damage) or 
neuron-specific enolase (NSE, marker of neuronal damage) despite an increased incidence of 
hypoglycemia [73]. Interestingly, patients who experienced an episode of hypoglycemia in ICU had 
higher S100B and NSE levels, but already from admission onwards and thus before the hypoglycemic 
event. Furthermore, a nested case-control study showed that both markers decreased after 
hypoglycemia unlike in the corresponding controls evaluated on the matched days [73]. This may 
reflect an increased incidence of hypoglycemia in the most severely ill patients, rather than elevated 
neurological damage markers being caused by hypoglycemia. More importantly, four years after ICU 
admission, children who had been treated with tight glucose control during their stay in ICU did not 
score worse on any measure of intelligence than those who had received the conventional glucose 
management, and actually showed better motor coordination and cognitive flexibility [74]. A brief 
episode of hypoglycemia evoked by tight glucose control did not negatively affect neurocognitive 
outcome, as shown in a propensity score-matched subgroup of children with and without 
hypoglycemia. Also, in patients with type 1 diabetes, no evidence of substantial long-term declines in 
cognitive function with IIT was found in a large group of patients who were followed up for an 
average of 18 years [75]. 
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CONCLUSIONS AND PERSPECTIVES 
Severe disturbances in glucose homeostasis may contribute to brain dysfunction and injury during 
critical illness. Prolonged hyperglycemia is associated with significant brain alterations in patients 
with or without acute brain injury. Maintaining normoglycemia with insulin infusion during critical 
illness holds promise to preserve brain cell viability and to prevent acute brain dysfunction as well as 
long-term cognitive impairment in survivors of critical illness, but requires further thorough 
investigation in well-designed, well-performed adequately powered randomized clinical studies. The 
impact of brief hypoglycemia on the brain in critical illness remains controversial. Hypoglycemia 
should be corrected promptly, avoiding overcorrection with excessive glucose reperfusion. 
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FIGURE LEGENDS 
 
Fig. 1 Glucose transport and substrate shuttling in the brain 
A : Glucose enters the brain interstitium via the 55 kDa GLUT1 transporter in the luminal and 
abluminal plasma membranes of blood–brain barrier endothelial cells. Neurons take up glucose via 
GLUT3 transporters, convert it to pyruvate via glycolysis (yielding 2 ATP per molecule of glucose) 
and metabolize it further via the tricarboxylic acid (TCA) cycle and oxidative phosphorylation 
(yielding 17 ATP per molecule of pyruvate). Glucose is delivered to the astrocytes via the 45 kDa 
GLUT1 transporter in the plasma membranes of astrocytic end-feet. Astrocytes also contain a small 
glycogen stock (not shown) that can be mobilized on brain activation and subsequently refilled with 
blood glucose.  
B : During neural activity, neuronal depolarization induces an influx of sodium which in turn 
contributes to liberation of glutamate (Glu). Intracellular ATP is used by the Na/K ATPase in order to 
restore ionic homeostasis. The ATP concentration in the neurons ([ATP]i) decreases, thereby releasing 
the negative feedback of ATP on the glycolytic enzymes (hexokinase, phosphofructokinase, and 
pyruvate kinase) and stimulating glycolysis. Brain activation is associated with increased activity at 
glutamatergic synapses and the released glutamate is taken up by the astrocytes in cotransport with 
sodium (via specific glutamate transporters). The intracellular sodium load in astrocytes is removed 
via the Na/K pump that consumes ATP and thereby stimulates astrocytic glycolysis. During intense 
neuronal activation or when glucose is lacking, lactate, the endproduct of glycolysis in astrocytes (by 
conversion from pyruvate via LDH5), leaves the cells via MCT1 mono-carboxylate transporters and is 
taken up by the neurons via MCT1 and MCT2 (astrocyte–neuron lactate shuttle hypothesis). In the 
neurons, lactate is converted to pyruvate via LDH1 and is further degraded oxidatively. Glutamate is 
recycled via the glutamate–glutamine (gln) cycle acting between astrocytes and neurons.  
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TABLES 
 
Table 1 Glucose and monocarboxylate transporters in the brain   
 Location  
in the brain 
Brain  
cell type(s) 
 
Km (*) 
Insulin 
sensitivity 
GLUT1 Widespread 
 
Astrocytes, choroid 
plexus, ependymal cells 
(Iso-45) 
Endothelium (Iso-55) 
5-8 mM No 
GLUT2 Hypothalamus 
 
Glucosensing cells : 
Astrocytes, neurons  
15-20 mM No 
GLUT3 Widespread 
 
Neurons 
(Neuropil) 
1-3 mM No 
GLUT4 Widespread Neurons  
(somatodendritic) 
4-5 mM Yes 
GLUT5 Widespread Microglia (**) No 
GLUT8 Widespread Neurons  
(somatodendritic) 
2 mM Yes 
MCT1 Widespread Neurons, astrocytes 
Microglia  
Choroïd plexus 
3-5 mM No 
MCT2 Widespread Neurons 0.5-0.7 mM No 
MCT3 Widespread Neurons  
Choroid plexus 
6 mM No 
MCT4 Widespread Astrocyte 8-30 mM No 
 
GLUT: glucose transporter, MCT: monocarboxylate transporter. 
(*): Only for GLUT1, GLUT3, MCT1, MCT2 and MCT4 reported Km values have been obtained for 
brain cells. Km values are given for glucose (GLUTs) or lactate (MCTs). A higher Km indicates a 
lower affinity. 
(**): Glucose transport activity reported for rat GLUT5 but not for human GLUT5.  
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Table 2 Randomized controlled studies in critically ill patients with acute brain injury 
comparing normoglycemia versus tolerating hyperglycemia 
 
Author 
year 
n Population Design Glucose 
targets 
(mmol/l) 
Glucose 
achieved 
(mmol/l) 
Primary outcome Effect of 
intervention/ 
Interpretation 
Van den 
Berghe 
2005 
63 Critically ill 
neurologic 
patients 
(isolated brain 
injury) 
IIT 
vs 
CONV 
 
4.4-6.1 
vs 
< 12.0 
 
5.7 
vs 
8.5 
Intracranial 
pressure levels 
 
Reduction of 
intracranial pressure 
levels 
Reduction of 
seizures and diabetes 
insipidus 
Improved long-term 
rehabilitation 
Azevedo 
2007 
50 Acute 
neurological 
injury 
 
IIT 
vs 
CONV 
4.4-6.7 
vs 
<10.0 
7.7 
vs 
8.2 
90-day extended 
Glasgow Coma 
Outcome Scale 
No effect on 
mortality 
No effect on 
neurological 
outcome 
Bilotta 
2007 
 
78 Acute 
subarachnoid 
hemorrhage 
 
IIT 
vs 
CONV 
 
4.4-6.7 
vs  
4.4-12.2 
NR Infection rate Lower infection rate 
Similar incidence of 
vasospasm 
No effect on 6-
months mortality 
No effect on 
neurological 
outcome 
Bilotta 
2008 
97 
 
Traumatic 
brain 
injury 
IIT 
vs 
CONV 
4.4-6.7  
vs  
< 12.2 
5.1 
vs 
8.2 
Incidence  
of 
hypoglycemia 
Increased incidence 
of hypoglycemia 
below 4.4 mmol/l 
Lower ICU length of 
stay 
No effect on 6-
month neurological 
outcome, infection 
rate or mortality 
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Table 2 Randomized controlled studies in critically ill patients with acute brain injury 
comparing normoglycemia versus tolerating hyperglycemia (continued) 
 
Author 
year 
n Population Design Glucose 
targets 
(mmol/l) 
Glucose 
achieved 
(mmol/l) 
Primary outcome Effect of 
intervention/ 
Interpretation 
Yang 
2009 
 
240 Traumatic brain 
injury 
IIT 
vs 
CONV 
4.4-6.1 
vs 
< 11.1 
 
NR 6-month 
 mortality 
 
No effect on 
mortality 
Lower infection 
rate ; shorter stay 
Better neurological 
outcomes 
Bilotta 
2009 
483 Post-operative 
neurosurgery 
IIT 
vs 
CONV 
4.4-6.1  
vs  
< 11.9 
5.1 
vs 
8.0 
Incidence  
of hypoglycemia 
 
Increased incidence 
of hypoglycemia 
Lower ICU length of 
stay  and infection 
rate  
No effect on 6-
month neurological 
outcome or mortality 
Green 
2010 
81 Critically ill 
neurologic 
patients 
IIT 
vs 
CONV 
4.4-6.1 
vs 
< 8.3  
NR 3-month  
mortality 
 
No effect on 
mortality or length 
of stay 
No effect on 
neurological 
outcome 
Coester 
2010 
88 Severe 
traumatic brain 
injury 
IV IIT 
vs 
SC 
CONV 
4.4-6.1 
vs 
< 10.0 
6.9 
vs 
8.1 
6-months Glasgow 
Outcome Scale 
No effect on 
neurological 
outcome, length of 
stay or incidence of 
sepsis  IIT: intensive insulin therapy, CONV: conventional glucose management, NSE: neuron-specific enolase, SC: subcutaneous; NR: not reported. [55, 57-63] 
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